In addition to lowering low-density lipoprotein cholesterol, statins improve vascular function by cholesterol-independent effects in experimental models. These extrahepatic effects are often called "pleiotropic"; however, specific underlying molecular mechanisms have been identified in animal and cell culture studies. They relate to the inhibition of isoprenylation of small G proteins. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase blocks the synthesis of isoprenoids, which are upstream of cholesterol (1, 2) . Therefore, statins inhibit isoprenoid and cholesterol synthesis at the same time, making it difficult to assess the relative contribution of the 2 for the reduction of vascular events. One could speculate that their importance may depend on the clinical situation. There is no doubt regarding the long-term importance of low-density lipoprotein cholesterol for atherogenesis. The isoprenoid-dependent effects (Fig. 1) , however, may be especially important for the acute effects of statin treatment.
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In their elegant paper in this issue of the Journal, Antoniades et Ϫ and ONOO Ϫ in the atrial myocardium from 303 patients undergoing cardiac surgery were associated with increased risk of atrial fibrillation, the need for postoperative inotropic support, and the length of hospital stay after surgery. They confirmed these data in a small prospective study (n ϭ 42) showing that preoperative atorvastatin treatment suppressed atrial NADPH oxidase activity and myocardial O 2 Ϫ and ONOO Ϫ production. Their data extend previous findings that showed that prospective shortterm oral statin treatment of patients with ischemic heart disease is able to down-regulate Rac1 activation and superoxide-producing NADPH oxidase activity in the right atrium (4, 5) .
In a parallel publication, Antoniades et al. (6) show a rapid beneficial regulation of vascular nitric oxide (NO) bioavailability and reduced O 2 Ϫ in samples of the internal mammary arteries. Statins increased vascular tetrahydrobiopterin bioavailability by up-regulating GTP-cyclohydrolase I, resulting in improved endothelial NO synthase coupling and reduced vascular O 2 Ϫ (6). This mechanism adds additional information on the rapid up-regulation of endothelial NO production by statins (7) .
As all good studies, this paper and the reports of other authors on acute statin effects raise further questions such as the details of the signaling and the exact time course of the cholesterol-independent events. If the very rapid effects are mediated by inhibition of isoprenylation, as proposed, the cells have to be very rapidly depleted of isoprenoids and isoprenylated proteins by the statin treatment. To understand this observation, the kinetics of isoprenoid turnover in different cell types and cellular compartments would be of interest. Similarly, intracellular statin concentrations and kinetics are poorly understood. Are specific drug transporters important? Do lipophilic statins differ from more hydrophilic drugs with regard to acute effects because of their very different serum concentrations? There are no convincing clinical data supporting this assumption. An (unproven) explanation could be that cholesterol-independent effects could be mediated by inhibition of HMG-CoA reductase in the cardiovascular cell or in the liver with inhibition of hepatic mevalonate synthesis, resulting in secondary systemic isoprenoid depletion in peripheral cells. If that is the Furthermore, in light of the accumulated mechanistic data, the most important future issue from the perspective of patient care is the relevance of the rapid statin effects for clinical endpoints. Indeed, it seems to be time to move to definitive prospective clinical trials testing acute effects of statins.
To study the acute effects of statins, oral application may not be sufficient, but an intravenous formulation, which is not available at the moment, could be helpful. Potential patient groups who may benefit from the proposed intravenous statins are shown in Table 1 . They include patients with acute coronary syndromes for whom high-dose oral statin therapy was shown to be beneficial and "re-loading" for percutaneous coronary interventions improved outcomes (8, 9) . A single oral dose of statin was shown to improve endothelium-dependent coronary vasomotion after 24 h in the absence of significant cholesterol reduction (10). Moreover, statins rapidly improved endothelial vasodilation and decreased serum markers of oxidative stress and inflammation independent of cholesterol lowering in patients with normal low-density lipoprotein cholesterol (11) . Furthermore, patients with ischemic strokes appear to benefit from early statin treatment (12, 13) . The effectiveness of an intravenous statin formulation was tested in a mouse model of focal brain ischemia, in which intravenous rosuvastatin reduced lesion size when given as long as 4 h after ischemia. Compared to intraperitoneal treatment, the intravenous administration extended the treatment window for ischemic stroke by 3 h (14) . Recent clinical evidence points toward reduced risk of myocardial infarction and death for patients with vascular risk who are undergoing surgery and are receiving statin treatment (15) . Statins have been shown to prevent atrial fibrillation in situations of risk such as surgery by mechanisms related to inhibition of small G protein isoprenylation (16, 17) .
Conversely, these beneficial rapid effects may also become relevant when statin treatment is stopped in patients at high risk or situations of high risk (18) . Sudden discontinuation of statin medication may exert negative effects on patients with acute vascular syndromes, whereas for stable vascular patients, discontinuation may not be a problem. The proposed mechanism again relates to the isoprenoid intermediates of the cholesterol synthesis pathway. Withdrawal of statin treatment confers overshoot activation of the small G-proteins RhoA and Rac1, causing production of reactive oxygen species and suppression of NO bioavailability (19) . An intravenous formulation could be helpful for all patients at high vascular risk who are unable to take oral statins for various reasons (e.g., being on a ventilator), to take advantage of positive acute effects and to prevent withdrawal, especially in high-risk situations such as acute coronary or cerebral ischemia and surgery.
In summary, the studies by Antoniades et al. (3, 6) provide important insights into the cholesterol-independent effects of statins on vascular and myocardial tissue. These studies are good examples of translational research confirming ex-vivo observations in human tissue and in hypothesis-generating clinical studies. As much as additional cellular studies are necessary to fully understand the signal transduction underlying the acute effects of statins, the main challenge for the future is to test the clinical relevance of statins by performing prospective trials with clinical endpoints.
Potential Indications for the Development of an Intravenous Statin Formulation Table 1 Potential Indications for the Development of an Intravenous Statin Formulation
